Posters & Presentations
Gateway Analytical is well-represented at top technical conferences around the globe, where our scientists often present on our unique capabilities and findings. Our posters and slides are below.
Bringing the latest conference to your desktop.
AAPS 2017 Development and Validation of a cGMP Compliant Particulate Characterization Database
Reference databases catalog data and information for known materials, process and product related materials, and archived foreign particulate.
RDD 2014: Chemically Specific Analysis of OINDPs: Differentiation of Drug Particle Agglomeration by Raman Chemical Imaging
Proper characterization of pharmaceutical products with respect to particle size and distribution requires that the extent and size of drug particle agglomerates is determined,
PDA 2016 Annual Meeting: Proactive Versus Reactive Testing for Glass Delamination in Pharmaceuticals
Authors & ContributorsEmily Landsperger
RDD 2015 Workshop: Assessing Aggregate Performance and the Presence of Foreign Particulate in OINDPs
May 19, 2015 Establishing bioavailability and proving bioequivalence of inhaled combination therapies can be difficult without addressing two major concerns: accurate and precise particle size distribution data of the individual active pharmaceutical ingredient and source determination of the any existing foreign particulate matter. Raman spectroscopy and Raman chemical imaging have…
Gateway Analytical to Present at 2012 MAAFS Meeting: The Introduction of Hyperspectral Imaging as an Additional Method of Examination for Tapes
Authors & Contributors Cara Plese May 10, 2012 The Mid-Atlantic Association of Forensic Scientists (MAAFS) annual meeting is being held later this month from May 14th through the 18th. MAAFS is one of several regional/state forensic science associations in the United States. Regional meetings are great for scientists to attend because they usually require less travel than…
2017 RDD Europe: Advancing the Determination of In Vitro Similarity in Tiotropium Formulations for Inhalation
Download our presentation from 2017 RDD Europe on Advancing the Determination of In Vitro Similarity in Tiotropium Formulations for Inhalation.
AAFS 2013 Presentation: What Judges and Lawyers Need to Know about the Science Behind Trace Evidence
Authors & ContributorsCara PleseAntonio Scatena
2018 PDA Annual Meeting: A Proactive Approach to the Particulate Management Lifecycle in Parenteral Drug Products
Authors & ContributorsDavid Exline, Cara Plese
2014 ASSA International IWPCPS-16 Workshops: Spatially-Resolved Raman Imaging for Ingredient-Specific Characterization of Combination Dry Powder Inhalers
June 17, 2014 Since the approval of Dry Powder Inhalers containing Fluticasone Propionate and Salmeterol Xinafoate in 1999, combination inhaled therapies have dominated the COPD market. However, due to the lack of specific guidance of the Office of Generic Drugs as to the abbreviated new drug application submission, there was…
2018 RDD Conference: Analysis of a Dry Powder Inhaler Active Pharmaceutical Ingredient Using Scanning Electron Microscopy
Download our presentation from 2018 RDD Conference on Analysis of a Dry Powder Inhaler Active Pharmaceutical Ingredient Using Scanning Electron Microscopy.
DDL 2014: Chemically-specific Characterization of Particulate in Inhalable Drug Products using Raman and Laser-induced Breakdown Spectroscopy
December 11, 2014 The impact of foreign particulate and agglomerates on dissolution profile and permeability of the inhalable drug particles within the sites of action (i.e. patient’s lungs) is critical. In this study, Raman Chemical Imaging (RCI) and Raman/ Laser-induced breakdown spectroscopy (LIBS) were used to investigate the Active Pharmaceutical…
2017 PDA Annual Meeting: Beyond the Count
Authors & ContributorsRebekah ByrneDavid ExlineEmily Landsperger
RDD 2013: Polymorph Identification of Drug Particles in Orally Inhaled and Nasal Drug Products
June 04, 2013 Authored by Oksana Olkhovyk, Ph.D., at Gateway Analytical , this poster presents new qualitative and semi-qualitative methods for the examination of size and polymorph drug particle identification in finished products. Specifically, its benefits for BA/BE testing is described using the model of fluticasone-containing nasal spray suspension formulation.…
AAPS 2012: Investigating the Miscibility of an API in Soluplus Dispersions by Raman Chemical Imaging Technique
October 18, 2012
IFPAC 2013 Presentation: Forensic Analysis of Foreign Particles in Pharmaceutical Materials
Authors & Contributors Rebekah Byrne
2014 IACP Conference: The Evolution of Gunshot Residue Analysis
Authors & Contributors David Exline Emily Landsperger Cara Plese November 19, 2014 Gunshot residue analysis is a common request in forensic laboratories with cases that question whether or not anindividual fired a firearm. When a firearm is fired, several types of residues are expelled from the openings on the firearm. Primer residues, specifically,…
DDL 2013: Raman-based Analysis of Dispersed Versus Aggregated Drug Particles in MDI Formulations for Chemically-specific Sizing and Polymorphic Purity Assessment
In this study, Raman Chemical Imaging (RCI) was used to investigate the active pharmaceutical ingredients (API) particle size distribution (PSD) and degree of drug
2017 AAPS Drug Dissolution for Foreign Particulate Analysis: Overcoming Challenges of MCC in Nasal Sprays
Foreign particulate matter in drug products is a common issue in the pharmaceutical industry that has major impacts on pharmaceutical companies, from both financial
RDD 2016: API-Specific Particle Size Distribution and Agglomerate Analysis using the rap.ID Single Particle Explorer (SPE)
The Active Pharmaceutical Ingredient (API) size distribution within the final formulation of a drug product is critical as it relates to bioavailability, rates of
Early-Phase Development
Container Closure
Integrity Testing
Particulate
Analysis
Medical Device
Analysis
Extractables
& Leachables
Empowering Your Journey Toward Enhanced Patient Care
Covering every stage of the drug development journey with our state-of-the-art, FDA-inspected, cGMP-compliant facilities designed to minimize bottlenecks and maximize success.